7/1/2020 11:15:42 AM
Akari Therapeutics Appoints Torsten Hombeck As CFO
7/1/2020 9:17:38 AM
Akari Therapeutics Appoints Torsten Hombeck CFO
9/13/2019 8:07:31 AM
Akari Therapeutics: FDA Grants Orphan Drug Designation For Nomacopan For Bullous Pemphigoid
8/30/2019 7:04:45 AM
Akari Therapeutics Says FDA Granted Orphan Drug Designation For Nomacopan
8/29/2019 8:13:49 AM
Akari Therapeutics Q2 Net Loss $4.1 Mln Vs Loss Of $8.0 Mln Last Year
4/23/2019 8:35:10 AM
Akari Therapeutics Announces Positive Initial Phase II Clinical Data In Orphan Skin Disease Bullous Pemphigoid
11/15/2018 6:51:26 AM
Akari Therapeutics Q3 Net Loss $3.6 Mln Vs Net Loss $10.4 Mln Last Year
9/27/2018 7:10:02 AM
Akari Therapeutics Q2 Net Loss $8.0 Mln Vs Loss Of $0.3 Mln Last Year
9/27/2018 7:07:27 AM
Akari Therapeutics Enters Securities Purchase Agreement For Up To $20 Mln With Aspire Capital Fund, LLC
9/12/2018 7:11:43 AM
Akari Reports New Preclinical Rheumatoid Arthritis Data And New Clinical Data In Patients With Bullous Pemphigoid
8/17/2018 7:03:49 AM
Akari Therapeutics Q1 Net Loss $1.3 Mln Vs Loss Of $12.6 Mln Last Year
3/21/2018 7:05:40 AM
Akari Therapeutics Q4 Net Loss Widens To $9.3 Mln From $8.3 Mln Last Year
2/6/2018 7:11:02 AM
Akari Therapeutics Announces Completion Of Phase II COBALT Trial Of Coversin In Patients With PNH